H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32

Moomoo News13:31 ET · Ratings

Iovance Biotherapeutics: Strong Financial Performance and Promising Clinical Advancements Drive Buy Rating

TipRanks12:45 ET · Ratings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Simply Wall StMar 1 09:35 ET

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations

Yahoo FinanceMar 1 09:12 ET

A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $6 to $23

Moomoo NewsMar 1 08:00 ET · Ratings

Iovance Biotherapeutics' Earnings Call Highlights Growth and Challenges

TipRanksFeb 28 19:41 ET